SAN JUAN CAPISTRANO, Calif.--(BUSINESS WIRE)--Robert Shahverdyan, MD, Head of the Vascular Access Center at Asklepios Klinik Barmbek in Hamburg, Germany, presented his experience performing Endovascular AV Fistula Creation (endoAVF) techniques at the Society of Interventional Radiology (SIR) 2019 Annual Meeting last month in Austin, Texas. In his presentation, he shared data that showed that the FDA cleared Ellipsys® Vascular Access System from Avenu Medical, Inc., was the preferred technique compared to other approaches.
Ellipsys, an innovative, minimally-invasive catheter-based system designed for End-Stage Renal Disease (ESRD) patients requiring hemodialysis, provides physicians and patients access to a unique non-surgical option for AV fistula creation. In his heavily attended presentation, considered to be the highlight of this year’s SIR event, Dr. Shahverdyan outlined the comparative benefits of using Ellipsys when compared to other available technology. Ellipsys’ benefits, as outlined by Dr. Shahverdyan, included: faster procedure time; no need for x-rays or contrast agents; and a simpler procedure to perform overall.
“Dr. Shahverdyan’s compelling analysis and data demonstrate that Ellipsys is faster and safer than any other approach,” said Ed Chang, Avenu’s Co-Founder and VP of Marketing. “And that it has clearly emerged as the gold standard for EndoAVF procedures.”
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
SIR 2019 was an active event for Avenu and Ellipsys. In addition to Dr. Shahverdyan’s presentation, another study centered around the use of Ellipsys, titled “The Pivotal Multicenter Trial of Ultrasound-Guided Percutaneous Arteriovenous Fistula Creation for Hemodialysis Access,” led by Jeffrey H.Hull, M.D. of Richmond Vascular Center, was selected by the editors of the Journal of Vascular and Interventional Radiology (JVIR) as the “Outstanding Clinical Study of the Year,” the Society’s top award. Dr. Hull’s paper was chosen by JVIR editorial board members, from among hundreds of reviewed manuscripts published in 2018 and singled out as the most essential, best-in-class research conducted in interventional radiology in the last year. The award was presented to Dr. Hull at SIR.
About Avenu Medical
Avenu Medical, Inc. was founded in 2010 to pursue unmet clinical needs in the ESRD and vascular access market. The company has developed the Ellipsys Vascular Access System which is an innovative, ultrasound-guided, single catheter endoAVF system used to percutaneously create an arteriovenous (AV) fistula for hemodialysis access.Back to HCB News